Business Description
Quince Therapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US22053A1079
Description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.1 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | -0.46 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.6 | |||||
| 3-Year EPS without NRI Growth Rate | 37.6 | |||||
| 3-Year FCF Growth Rate | 34.2 | |||||
| 3-Year Book Growth Rate | -30.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.18 | |||||
| 9-Day RSI | 55.53 | |||||
| 14-Day RSI | 58.54 | |||||
| 3-1 Month Momentum % | 116.33 | |||||
| 6-1 Month Momentum % | 127.83 | |||||
| 12-1 Month Momentum % | 60.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.53 | |||||
| Quick Ratio | 9.53 | |||||
| Cash Ratio | 8.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.3 | |||||
| Shareholder Yield % | -15.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -79.67 | |||||
| ROA % | -39.52 | |||||
| ROIC % | -50.55 | |||||
| 3-Year ROIIC % | 120.75 | |||||
| ROC (Joel Greenblatt) % | -5641.85 | |||||
| ROCE % | -27.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.95 | |||||
| EV-to-EBIT | -1.67 | |||||
| EV-to-Forward-EBIT | -1.41 | |||||
| EV-to-EBITDA | -1.69 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-FCF | -1.88 | |||||
| Earnings Yield (Greenblatt) % | -59.88 | |||||
| FCF Yield % | -34.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QNCX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Quince Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.24 | ||
| Beta | 1.62 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.28 | ||
| Volatility % | 118.71 | ||
| 14-Day RSI | 58.54 | ||
| 14-Day ATR ($) | 0.224918 | ||
| 20-Day SMA ($) | 1.978 | ||
| 12-1 Month Momentum % | 60.2 | ||
| 52-Week Range ($) | 0.5116 - 2.45 | ||
| Shares Outstanding (Mil) | 44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Quince Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Quince Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Quince Therapeutics Inc Frequently Asked Questions
What is Quince Therapeutics Inc(QNCX)'s stock price today?
The current price of QNCX is $2.03. The 52 week high of QNCX is $2.45 and 52 week low is $0.51.
When is next earnings date of Quince Therapeutics Inc(QNCX)?
The next earnings date of Quince Therapeutics Inc(QNCX) is 2025-02-13 Est..
Does Quince Therapeutics Inc(QNCX) pay dividends? If so, how much?
Quince Therapeutics Inc(QNCX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers